F3Logic’s Teva Pharmaceuticals TEVA Stock Holding History

F3Logic’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-50	Closed	-$451	–	404
2020 Q3	$451	Buy	+50	New	+$529	0.01%	362

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

F3Logic's TEVA Position: Q4 2020 in Review

F3Logic sold out of Teva Pharmaceuticals (TEVA) in Q4 2020, closing a stake of 50 shares — an estimated $451 sold.

F3Logic first reported a position in TEVA in Q3 2020 and held it in 1 quarter. The position peaked at $451 in Q3 2020. 449 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

F3Logic reported no remaining Teva Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
F3Logic sold 50 Teva Pharmaceuticals shares in Q4 2020, an estimated $451.
F3Logic first reported a position in Teva Pharmaceuticals in Q3 2020 and held it in 1 quarter.
F3Logic's Teva Pharmaceuticals position peaked at $451 in Q3 2020.
449 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on F3Logic's 13F filing for Q4 2020, filed 12 Feb 2021.